Dark

Check out our Dark Pool Levels

TMBR
Timber Pharmaceuticals, Inc.
stock NYSEAMERICAN

Inactive

Nov 29, 2023 8:03:00 AM EST

0.3532USD+3.094%(+0.0106)322,140

Pre-market

0.00USD-100.000%(-0.34)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

08:00AM EST Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect GlobeNewswire Inc

Dec 13, 2021

09:43AM EST Overview Of Value Stocks In The Healthcare Sector Benzinga

Nov 17, 2021

04:18PM EST Timber Pharmaceuticals to Host Conference Call Discussing Positive GlobeNewswire Inc

Nov 15, 2021

05:20PM EST Timber Pharmaceuticals Q3 EPS $(0.08) Down From $0.14 YoY, Sales $266.97K Down From $324.52K YoY Benzinga

Nov 5, 2021

04:05PM EDT Timber Pharmaceuticals Announces Closing of $15 Million Public GlobeNewswire Inc

Nov 3, 2021

02:37PM EDT Mid-Afternoon Market Update: Nasdaq Rises 60 Points; Federal Reserve Slows Down Bond Buying Benzinga

12:15PM EDT Mid-Day Market Update: Crude Oil Drops Over 3%; R.R.Donnelley & Sons Shares Jump Benzinga

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:17AM EDT Timber Pharma Prices ~23.44M Share Offering At Stock, Warrants At $0.64/Share, Warrant Benzinga

08:00AM EDT Timber Pharmaceuticals Announces Pricing of $15 Million Public GlobeNewswire Inc

06:39AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.15 A.M. EDT). RTTNews

Nov 2, 2021

05:03PM EDT Timber Pharma Reports Offering Of Common Stock, No Size Disclosed Benzinga

Oct 7, 2021

09:14AM EDT Timber Pharma Reports Top-Line Results From Phase 2b CONTROL Study Evaluating TMB-001 In Moderate To Severe Congential Ichthyosis Benzinga

09:12AM EDT -- Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG TMB-001 (topical isotretinoin) -- Company planning for end-of-Phase 2 meeting with FDA in the beginning of 2022 -- Phase 3 study is expected to begin in Q2 2022 GlobeNewswire Inc

Oct 1, 2021

08:00AM EDT Timber Pharmaceuticals Presents at EADVs 30th GlobeNewswire Inc

Sep 10, 2021

05:59PM EDT Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd GlobeNewswire Inc

Aug 30, 2021

10:22AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Aug 24, 2021

08:07AM EDT Timber Pharmaceuticals Announces Last Patient Last Visit In Phase 2b CONTROL Study Evaluating TMB-001 In Moderate To Severe Congenital Ichthyosis Benzinga

08:00AM EDT - Topline results expected to be announced in the fourth quarter of 2021 - GlobeNewswire Inc

Aug 10, 2021

08:25AM EDT Timber Pharmaceuticals Q2 EPS $(0.08) Up From $(1.36) YoY Benzinga

08:00AM EDT via NewMediaWire--Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2021. GlobeNewswire Inc

Jun 3, 2021

04:05PM EDT Timber Pharmaceuticals Announces Adjournment of Annual Meeting GlobeNewswire Inc

May 27, 2021

08:51AM EDT Timber Pharma Shares Jump As Mid-Stage Skin Disorder Study With TMB-001 Concludes Enrollment Early Benzinga

May 26, 2021

04:06PM EDT Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis Benzinga

04:05PM EDT - Company plans to ask for end-of-Phase 2 meeting with FDA by end of 2021 - GlobeNewswire Inc

May 11, 2021

04:55PM EDT Timber Pharmaceuticals Q1 EPS $(0.05) Up From $(0.56) YoY, Sales $40.73K Up From $26.91K YoY Benzinga

04:39PM EDT via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

May 4, 2021

09:14AM EDT Timber Pharma S-3 Shows Registration For $100M Mixed Securities Shelf Offering Benzinga

Apr 28, 2021

08:27AM EDT Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001 Benzinga

08:00AM EDT - Company is evaluating a topical pharmaceutical composition of isotretinoin for the treatment of moderate to severe subtypes of congenital ichthyosis - GlobeNewswire Inc

Apr 23, 2021

08:05AM EDT Timber Pharma Names John Koconis Chair Benzinga

08:00AM EDT - Edward J. Sitar appointed as Lead Independent Director of the Board - GlobeNewswire Inc

Apr 2, 2021

04:05PM EDT Timber Pharmaceuticals Sets Record Date for Annual Meeting of GlobeNewswire Inc

Mar 23, 2021

04:19PM EDT Timber Pharmaceuticals FY20 Grant Revenue $500K Benzinga

04:05PM EDT 50% of patients in the Phase 2b CONTROL study have now been randomized despite COVID-19 disruptions in the trial marketplace GlobeNewswire Inc

Mar 17, 2021

08:03AM EDT Timber Pharma Reports Its Development Partner, AFT Pharma, Entered License Deal For Pascomer In Europe Benzinga

08:00AM EDT - Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe - GlobeNewswire Inc

Mar 15, 2021

08:34AM EDT Timber Pharmaceuticals Announces 50% Enrollment In Phase 2b CONTROL Study In Congenital Ichthyosis Benzinga

08:30AM EDT - Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder GlobeNewswire Inc

Mar 5, 2021

08:30AM EST Timber Pharmaceuticals Announces Presentation at 2021 H.C. GlobeNewswire Inc

Feb 16, 2021

12:46PM EST 43 Stocks Moving In Tuesday's Mid-Day Session Benzinga

Jan 27, 2021

05:29AM EST Pre-market Movers In Healthcare Sector: TMBR, AEZS, SRNE, RTTNews

Jan 25, 2021

04:07PM EST Timber Pharmaceuticals Appoints Alan Mendelsohn As Chief Medical Officer Benzinga

04:05PM EST Dr. Mendelsohn has 20+ Years Experience in Clinical Development and Medical Affairs GlobeNewswire Inc

Jan 12, 2021

04:42PM EST Timber Pharma Shares Spike Higher Following Co. Press Release Highlighting Orphan Drug Designation For Systemic Sclerosis Treatment, BZ NOTE: The News Was Reported On The FDA Website In Late Monday Evening Benzinga

04:39PM EST Timber Pharma Shares Spike Higher Following Co. Press Release, BZ NOTE: The News Was Reported On The FDA Website In Early Tuesday Morning Benzinga

04:25PM EST Timber Pharmaceuticals Shares Spike Higher Following The Company's Press Release; BZ Note: News Was Out On FDA Website Early Tuesday Morning Benzinga

04:24PM EST Timber Shares Spike Following The Company's Press Release; BZ Note: News Was Out On FDA Website Early Tuesday Morning Benzinga

04:22PM EST Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022 GlobeNewswire Inc

05:05AM EST Timber Pharmaceuticals Received FDA Orphan Drug Designation on Monday for Sitaxentan for Treatment of Systemic Sclerosis Benzinga

Dec 15, 2020

08:29AM EST Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Dec. 15, 2020: FDX, XPEV, CWH, IMRN, TMBR Benzinga

08:00AM EST Timber Pharma Reports Notice Of Allowance From US Patent & Trademark Office For Lead Asset TMB-001 Benzinga

08:00AM EST - Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition - GlobeNewswire Inc

Dec 10, 2020

08:30AM EST Timber Pharmaceuticals Hosts Business Update Conference Call GlobeNewswire Inc

Dec 8, 2020

04:05PM EST Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main GlobeNewswire Inc

Nov 20, 2020

09:08AM EST Timber Pharmaceuticals Signs Waiver Agreement With Warrant Holders Benzinga

09:07AM EST Timber Pharma Signs Waiver Agreement With Warrant Holders RTTNews

09:05AM EST NewMediaWire-- Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors. GlobeNewswire Inc

Nov 12, 2020

04:59PM EST Timber Pharmaceuticals Reports Received $300K In Connection With FDA Grant For TMB-001 Benzinga

Sep 15, 2020

08:06AM EDT Timber Pharmaceuticals Receives Notice Of Allowance From US Patent And Trademark Office For BPX-01 And BPX-04 Benzinga

08:01AM EDT - Formal notice confirms intent to grant patent for pharmaceutical tetracycline compositions for dermatological use - GlobeNewswire Inc

Sep 11, 2020

04:30PM EDT Timber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual GlobeNewswire Inc

Aug 19, 2020

04:10PM EDT via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced the appointment of David Cohen, M.D. and Lubor Gaal, Ph.D. to its board of directors. GlobeNewswire Inc

Aug 18, 2020

04:13PM EDT Timber Pharmaceuticals Q4 EPS $(1.36) Benzinga

04:12PM EDT Timber Pharmaceuticals Says Phase 2b Clinical Trials for Each of the Company's Lead Assets in Orphan Dermatologic Diseases are Progressing as Planned Benzinga

04:10PM EDT Phase 2b Clinical Trials for Each of the Companys Lead Assets in Orphan Dermatologic Diseases are Progressing as Planned GlobeNewswire Inc

Jul 22, 2020

08:01AM EDT Timber Pharmaceuticals Announces European Patent Office Intends To Grant Patent For BPX-01 And BPX-04 Benzinga

08:00AM EDT Stable topical composition has potential to reduce side effects of orally delivered compositions in treatment of acne and rosacea GlobeNewswire Inc

Share